XNCR

Piper Sandler Downgrades Xencor (XNCR)

Fintel reports that on February 28, 2024, Piper Sandler downgraded their outlook for Xencor (NasdaqGM:XNCR) from Overweight to Neutral .

Analyst Price Forecast Suggests 77.53% Upside

As of February 24, 2024, the average one-year price target for Xencor is 40.46. The forecasts range from a low of 22.22 to a high of $61.95. The average price target represents an increase of 77.53% from its latest reported closing price of 22.79.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Xencor is 179MM, an increase of 6.31%. The projected annual non-GAAP EPS is -2.21.

What is the Fund Sentiment?

There are 500 funds or institutions reporting positions in Xencor. This is an increase of 8 owner(s) or 1.63% in the last quarter. Average portfolio weight of all funds dedicated to XNCR is 0.10%, a decrease of 16.49%. Total shares owned by institutions increased in the last three months by 0.19% to 75,850K shares. XNCR / Xencor, Inc. Put/Call Ratios The put/call ratio of XNCR is 0.28, indicating a bullish outlook.

What are Other Shareholders Doing?

XNCR / Xencor, Inc. Shares Held by Institutions

Primecap Management holds 8,902K shares representing 14.62% ownership of the company. In it's prior filing, the firm reported owning 8,184K shares, representing an increase of 8.06%. The firm increased its portfolio allocation in XNCR by 7.48% over the last quarter.

POAGX - PRIMECAP Odyssey Aggressive Growth Fund holds 5,672K shares representing 9.32% ownership of the company. In it's prior filing, the firm reported owning 5,541K shares, representing an increase of 2.31%. The firm decreased its portfolio allocation in XNCR by 15.69% over the last quarter.

EcoR1 Capital holds 5,283K shares representing 8.68% ownership of the company. No change in the last quarter.

IJR - iShares Core S&P Small-Cap ETF holds 4,075K shares representing 6.69% ownership of the company. In it's prior filing, the firm reported owning 4,093K shares, representing a decrease of 0.44%. The firm decreased its portfolio allocation in XNCR by 9.28% over the last quarter.

Price T Rowe Associates holds 3,484K shares representing 5.72% ownership of the company. In it's prior filing, the firm reported owning 3,185K shares, representing an increase of 8.58%. The firm increased its portfolio allocation in XNCR by 5.67% over the last quarter.

Xencor Background Information
(This description is provided by the company.)

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.